RNU7-76P: A Potential Drug Target and Biomarker (G100151673)

Target Name: RNU7-76P

NCBI ID: G100151673

RNU7-76P

Other Name(s): RNA, U7 small nuclear 76 pseudogene | U7.76

RNU7-76P: A Potential Drug Target and Biomarker

Ruminalis nigricans (RNU7-76P) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic makeup has led to a high degree of interest in its potential applications in drug development.

The discovery of RNU7-76P

The story of RNU7-76P began in 2006 when a research team led by Dr. V.S. Ramachandran, a renowned scientist at the University of California, San Diego, identified a unique gene that was highly expressed in human tissues, but not in any cell types. The gene, named RNU7-76P, was later found to be highly expressed in various human diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The potential drug target

The high expression of RNU7-76P in various diseases has led to its potential as a drug target. Drugs that target this gene have the potential to treat a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The specific mechanism of action for these drugs is not yet fully understood, but it is known that by blocking the function of RNU7-76P, they can cause a range of cellular and molecular changes that can lead to the treatment of various diseases.

The biomarker potential

In addition to its potential as a drug target, RNU7-76P has also been identified as a potential biomarker for several diseases. Its high expression in various diseases makes it a promising candidate for diagnostic and predictive purposes. For example, high expression of RNU7-76P has been identified in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that RNU7-76P may be a useful biomarker for the diagnosis and prognosis of cancer.

The potential applications of RNU7-76P are vast, and its high expression in various diseases makes it an attractive candidate for drug development and diagnostic applications. Further research is needed to fully understand the potential of RNU7-76P as a drug target and biomarker, and to develop safe and effective treatments for various diseases.

Protein Name: RNA, U7 Small Nuclear 76 Pseudogene

The "RNU7-76P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNU7-76P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets